Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
401
-
402
-
403
A Functional 12T-Insertion Polymorphism in the <i>ATP1A1</i> Promoter Confers Decreased Susceptibility to Hypertension in a Male Sardinian Population
Published 2015“…To test the effects of decreased α1Na,K-ATPase expression on blood pressure, we measured blood pressure by radiotelemetry in three month-old, highly inbred heterozygous knockout <i>ATP1A1+/−</i> male mice with resultant 58% reduction in ATP1A1 protein levels. …”
-
404
-
405
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
-
406
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
-
407
-
408
-
409
-
410
-
411
-
412
-
413
-
414
-
415
-
416
Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines.
Published 2021“…Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
-
417
-
418
-
419
-
420